ALX Oncology (ALXO) Director Daniel Curran Receives Award

What Happened

• Daniel J. Curran, a director of ALX Oncology Holdings, was granted a derivative award covering 16,833 shares on January 20, 2026. The filing reports an acquisition price of $0.00 and a reported dollar value of $0. This is an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-20; Form 4 filed: 2026-01-21 (timely — within the usual two-business-day requirement).
• Transaction type/code: A (award/grant, derivative security).
• Shares/units granted: 16,833; reported acquisition price: $0.00; reported value: $0.
• Vesting: Footnote — shares subject to the option vest in 12 equal monthly installments beginning February 20, 2026 (i.e., monthly through Feb 2027).
• Shares owned after transaction: not specified in the provided summary of the filing.
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context

• This was a grant of a derivative award (the filing refers to an option); the award vests monthly over one year. Awards/vesting are compensation actions and do not by themselves signal intent to buy or sell stock. Retail investors should view this as routine insider compensation unless accompanied by other transactions.